| KVUE |
Report |
Adj. diluted EPS (Q2'26) |
BEAT |
pred ~$0.31 vs. cons ~$0.30 |
MEDIUM |
| KVUE |
Report |
Organic sales growth (Q2'26) |
BEAT |
pred ~+1.5% vs. cons ~+0.8% |
MEDIUM |
| KVUE |
Report |
Net sales (Q2'26) |
IN-LINE |
pred ~$3,900M vs. cons ~$3,875M |
MEDIUM |
| KVUE |
Guide |
FY26 outlook (guidance suspended pending KMB deal) |
UNKNOWN |
guide none/suspended vs. cons FY26 adj EPS ~$1.20 (FY26) — no call, no guidance |
HIGH |
| KVUE |
Guide |
Deal close timeline (KMB acquisition) |
UNCHANGED |
guide H2 2026 close vs. cons H2 2026 (2H26) |
HIGH |
| KVUE |
Guide |
Implied deal value vs. spread (0.14625 KMB + $3.50, KMB $112.40) |
UNCHANGED |
implied ~$19.94 vs. KVUE ~$19.66 (~1.4% gross spread) |
HIGH |
| KVUE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.4% |
— |
MEDIUM |
| KVUE |
Return |
5-day cumulative residual |
+0.3% (STABILIZE) |
KVUE is a late-stage merger-arb name (~82% KMB stock + $3.50 cash), so the print is academic — no call, no guidance, U.S. HSR + EU-FSR cleared, H2'26 close intact. The stock tracks the KMB exchange ratio and deal spread, not its own KPIs; even a modest beat on easy comps won't re-rate the ~1.4% spread. KMB already reported (8/4, EPS $2.12 beat, trimmed FY guide) and rose, so payout math is set. Residual return stays near zero absent a MAC/EU-review scare or KMB drawdown; spread grinds tighter into close. |
MEDIUM |